This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 1 of 1 for:    NCT04047290
Previous Study | Return to List | Next Study

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04047290
Recruitment Status : Recruiting
First Posted : August 6, 2019
Last Update Posted : October 28, 2022
Information provided by (Responsible Party):
Akeso ( Akesobio Australia Pty Ltd )

Brief Summary:
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK112 as a single agent at the MTD or RP2D.

Condition or disease Intervention/treatment Phase
Neoplasms Malignant Drug: AK112 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 151 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential Assignment Initially, a single-subject cohort will be enrolled at the protocol starting dose of AK112 every 2 weeks (Q2W). Dose escalation will proceed to the next main dose level according to the 3+3+3 dose-escalation procedure until the MTD is reached. Dose expansion phase of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose-escalation phase.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors
Actual Study Start Date : September 20, 2019
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : August 30, 2024

Arm Intervention/treatment
Experimental: AK112
AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
Drug: AK112
AK112 is a PD1/VEGF bispecific antibody.

Primary Outcome Measures :
  1. Incidence and nature of participants with adverse events (AEs) [ Time Frame: From time ICF is signed until 90 days after last dose of AK112 ]
    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

  2. Number of participants with DLTs [ Time Frame: During the first four weeks of treatment with AK112 ]
    DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 2 years ]
    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.

  2. Disease control rate (DCR) [ Time Frame: Up to 2 years ]
    The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD at 16 and 24 weeks respectively) based on RECIST Version 1.1.

  3. Progression-free survival (PFS) [ Time Frame: Up to 2 years ]
    Progression-free survival is defined as the time from the start of treatment with AK112 until the first documentation of disease progression or death due to any cause, whichever occurs first.

  4. Overall survival (OS) [ Time Frame: Up to 2 years ]
    Overall survival is defined as the time from the start of treatment with AK112 until death due to any cause.

  5. Area under the curve (AUC) of AK112 for assessment of pharmacokinetics [ Time Frame: From first dose of AK112 through 90 days after last dose of AK112 ]
    The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.

  6. Maximum observed concentration (Cmax) and Minimum observed concentration (Cmin) of AK112 [ Time Frame: From first dose of AK112 through 90 days after last dose of AK112 ]
    The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.

  7. Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK112 through 90 days after last dose of AK112 ]
    The immunogenicity of AK112 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
  • In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
  • In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.
  • Subject must have at least one measurable lesion according to RECIST Version1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
  • Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
  • Adequate organ function.
  • Subjects with central nervous system (CNS) metastases must have been treated, be asymptomatic.
  • Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.
  • Life expectancy ≥12 weeks.

Exclusion Criteria:

  • History of severe hypersensitivity reactions to other mAbs.
  • Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or breast).
  • For subjects enrolled in the dose escalation phase, having received prior anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with AK112 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids
  • Receiving any immunotherapy, conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose
  • Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment (hormones use for non-cancer related conditions is acceptable).
  • Subjects with clinically significant cardiovascular disease
  • Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.
  • Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
  • Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of AK112
  • Active or prior documented autoimmune disease within the past 2 years or conditions not expected to recur in the absence of an external trigger)
  • Active or prior documented inflammatory bowel disease
  • History of primary immunodeficiency.
  • History of organ transplant.
  • Known allergy or reaction to any component of the AK112 formulation.
  • History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
  • Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1
  • Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery.
  • Known history of HIV.
  • Known active hepatitis B or C infections. Note: Subjects with HCC and positive HBsAg result are eligible if the subjects were treated with antiviral therapy and HBV viral load less than 500 IU/mL prior to first dose of AK112.
  • An active infection requiring systemic therapy
  • Received live attenuated vaccination within 30 days prior to the first dose of AK112.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04047290

Layout table for location contacts
Contact: Baiyong Li +86 (0760) 8987 3999

Layout table for location information
Australia, New South Wales
Border Medical Oncology Completed
Albury, New South Wales, Australia
Scientia Clinical Research Ltd Recruiting
Randwick, New South Wales, Australia
Contact    +61 2 9382 5811      
Principal Investigator: Charlotte Lemech, MBBS         
Blacktown Hospital Recruiting
Sydney, New South Wales, Australia
Contact: Natalie Byrne   
Principal Investigator: Adnan Nagrial, MBBS         
Australia, Queensland
ICON Cancer Foundation Recruiting
South Brisbane, Queensland, Australia
Contact    +61 3737 4500      
Principal Investigator: Jermaine Coward, MBBS         
Australia, South Australia
Adelaide Cancer Centre Recruiting
Kurralta Park, South Australia, Australia
Contact    +61 8 8292 2220      
Principal Investigator: Anna Mislang, MBBS         
Australia, Victoria
Monash Health Recruiting
Clayton, Victoria, Australia
Contact: Sophia Frentzas, Dr    +61 3 8572 2429   
Principal Investigator: Sophia Frentzas, MBBS         
Peter MacCallum Cancer Centre Recruiting
Melbourne, Victoria, Australia
Contact: Linda Mileshkin, MBBS    +61 3 8559 5000      
Sponsors and Collaborators
Akesobio Australia Pty Ltd
Layout table for additonal information
Responsible Party: Akesobio Australia Pty Ltd Identifier: NCT04047290    
Other Study ID Numbers: AK112-101
First Posted: August 6, 2019    Key Record Dates
Last Update Posted: October 28, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Akeso ( Akesobio Australia Pty Ltd ):
anti-PD-1/VEGF bispecific antibody
advanced solid tumors
Additional relevant MeSH terms:
Layout table for MeSH terms